Phenylketonuria Treatment Market Competitive Landscape with Top Players BioMarin, Dimension Therapeutics,American Gene Technologies, Synthetic Biologics
Phenylketonuria (PKU) is a rare genetic disorder caused due to increased level of phenylalanine in the blood. The excess amount of phenylalanine can cause intellectual disability and other serious health problems. The most severe condition of this disorder is termed as classic PKU and symptoms related to it are seizures, tremors, or trembling and shaking, stunted growth, hyperactivity, skin conditions such as eczema, and musty odor of their breath, skin, or urine. PKU can be managed by maintaining phenylalanine free diet. KUVAN (sapropterin dihydrochloride) is a U.S. Food and Drug Administration approved drug which is majorly used in the treatment of Phenylketonuria.Phenylketonuria Treatment Market Drivers
Frequent research for development of novel drugs for the treatment of phenylketonuria is expected to drive growth of global phenylketonuria treatment market in the near future. For instance, in 2017, BioMarin Pharmaceutical Inc. submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its new Pegvaliase, indicated for the treatment of patients with Phenylketonuria (PKU). In 2018, European Medicines Agency (EMA) accepted BioMarin’s submission of a Marketing Authorization Application (MAA) for pegvaliase for the treatment of adults with phenylketonuria (PKU) who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 micromol/l). In 2017, Synlogic, Inc. received Orphan Drug Designation for its SYNB1618 from U.S. Food and Drug Administration. SYNB1618, an orally administered synthetic biotic medicine indicated for the treatment of PKU.
Request A Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/1648
Furthermore, increasing acquisitions and collaborations between key players is also expected to create a lucrative environment for growth of global phenylketonuria treatment market. For instance, in 2015, BioMarin Pharmaceutical Inc. acquired all global rights of Kuvan (sapropterin dihydrochloride) and pegvaliase from Merck Serono (Merck). Kuvan is an oral therapy indicated for the treatment of hyperphenylalaninemia (HPA) due to phenylketonuria (PKU). Pegvaliase (PEGylated recombinant phenylalanine ammonia lyase) is an investigational enzyme substitution therapy for the treatment of phenylketonuria (PKU). In 2016, Dimension Therapeutics, Inc. entered into a gene therapy research collaboration with the University of Pennsylvania for research and development of novel treatment for phenylketonuria.
Phenylketonuria Treatment Market Regional Analysis
North America is expected to hold a dominant position in global phenylketonuria treatment market, owing to initiatives taken by governments for the diagnosis and treatment of phenylketonuria in the region. For instance, in 2017, The National PKU Alliance and Baby Genes launched a program to allow easy access to genetic testing for people with phenylketonuria, and their families. The program aims to help in diagnosis and assist the people for treatment of phenylketonuria. Furthermore, launches of novel products by U.S.-based key players is also expected to drive growth of North America phenylketonuria treatment market. For instance, in 2017, Vitaflo USA, LLC launched its new PKU Sphere, a low phenylalanine medical food used in dietary management of Phenylketonuria (PKU). Europe is also expected to exhibit significant growth in the near future, owing to increasing approval of new drugs in the region. For instance in 2015, Merck Group, a Germany-based company, received EU-approval to extend the use of Kuvan in children below four years of age suffering from Phenylketonuria.
Phenylketonuria Treatment Market Restraint
According to data published by The ZB Foundation in 2017, Phenylketonuria is a rare inherited disease that affects only about 1 in 10,000 to 15,000 newborn children. The lack of awareness about the rare disease is a major factor, which is expected to restrain growth of the market in the near future.
Phenylketonuria Treatment Market Key Players
Key players operating in global phenylketonuria treatment market include BioMarin Pharmaceutical Inc., Dimension Therapeutics, Inc., American Gene Technologies International Inc., Synthetic Biologics, Inc., Codexis, Inc., SOM Innovation Biotech SL, Daiichi Sankyo Company, Limited, and Erytech Pharma SA. Key Players in global phenylketonuria treatment market are focusing on strategic collaborations for the development of novel therapies for the treatment of phenylketonuria. For instance, in January 2018, Retrophin, Inc. and Censa Pharmaceuticals collaborated for the development and evaluation of CNSA-001 for the treatment of phenylketonuria (PKU). CNSA-001, is an orally bioavailable proprietary form of sepiapterin, serves as a natural precursor of tetrahydrobiopterin (BH4) that is converted by an endogenous enzymatic pathway to BH4.
Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1648
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Phenylketonuria Treatment Market Competitive Landscape with Top Players BioMarin, Dimension Therapeutics,American Gene Technologies, Synthetic Biologics here
News-ID: 1779595 • Views: …
More Releases from Coherent Market Insights
Magnesium Oxide Market Size 2024: New Opportunities, Geographical Analysis, and …
The latest report published by Coherent Market Insights highlights the growth prospects of the Magnesium Oxide Market from 2024 to 2031. In-depth research on Industry Size, Share, Business Analysis, Growth Factors, and Regional Forecast. The market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The market study includes information on market factors such…
Colostrum Market Key Growth Drivers, Latest Opportunities, Increasing Demand, an …
The latest report published by Coherent Market Insights highlights the growth prospects of the Colostrum Market from 2024 to 2031. In-depth research on Industry Size, Share, Business Analysis, Growth Factors, and Regional Forecast. The market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The market study includes information on market factors such as…
Steam Turbine Market Size 2024: Industrial Insights including Manufacturing Deta …
The latest report published by Coherent Market Insights highlights the growth prospects of the Steam Turbine Market from 2024 to 2031. In-depth research on Industry Size, Share, Business Analysis, Growth Factors, and Regional Forecast. The market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The market study includes information on market factors such…
Protein Supplements Market Share: Size, Growth, Key Vendors, Trends, and Forecas …
The latest report published by Coherent Market Insights highlights the growth prospects of the Protein Supplements Market from 2024 to 2031. In-depth research on Industry Size, Share, Business Analysis, Growth Factors, and Regional Forecast. The market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The market study includes information on market factors such…
More Releases for Phenylketonuria
Phenylketonuria (PKU) - Pipeline Review, H1 2018
"The Report Phenylketonuria (PKU) - Pipeline Review, H1 2018 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Phenylketonuria Market
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Phenylketonuria (PKU) - Pipeline Review, H1 2018, provides an overview of the Phenylketonuria (PKU) (Metabolic Disorders) pipeline landscape.
Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/1509364
Phenylketonuria (also called PKU), is a…
Phenylketonuria Market To Register Steady Growth During 2025
Phenylketonuria is a genetic disorder, which means it is inherited from one’s parents. In this disease, the patient suffers from a metabolic defect, wherein the body is unable to break down phenylalanine amino acid that is made of protein. Phenylalanine starts accumulating in the blood stream and eventually, it damages the brain. This happens due to mutations in the PAH gene, which result in low levels of the enzyme called…
Global Phenylketonuria Market 2017 Forecast to 2022
Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Phenylketonuria Market 2017 Forecast to 2022
TOC and List of Tables & Figures:
https://www.researchbymarkets.com/report/global-north-america-europe-and-asia-pacific-south-america-middle-east-and-africa-phenylketonuria-market-2017-forecast-to-2022-2694.html
This report studies the phenylketonuria market. Phenylketonuria is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorder. It may also result in a musty smell and lighter skin.…
Phenylketonuria (PKU) Market Research Report : 2017
Reports And Markets Publish a New Market Research Report On –"Phenylketonuria (PKU) Market Research Report 2017"
Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/global-phenylketonuria-pku-market-research-report-2017-1541147
In this report, the global Phenylketonuria (PKU) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Geographically, this report is segmented into several key Regions,…
Phenylketonuria (PKU) - Market Insights, Epidemiology, Outlook to 2025
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Phenylketonuria (PKU)-Market Insights, Epidemiology and Market Forecast-2025” to its report offerings. The report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Phenylketonuria (PKU).
Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1265871
The report provides an overview of the disease and in depth research related to Phenylketonuria (PKU) for the 7MM (United States,…
Phenylketonuria (PKU) - Pipeline Review, H2 2017
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Phenylketonuria (PKU) - Pipeline Review, H2 2017”. Phenylketonuria (also called PKU), is a rare inherited disorder that causes an amino acid called phenylalanine to build up in body. Symptoms include intellectual disability, psychiatric disorders, hyperactivity, skin rashes, poor bone strength and abnormally small head.
Request For Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1246570
Report Highlights
Global Markets Direct's Pharmaceutical and…